Early diagnosis saves lives
GenSure Biotech, in collaboration with Diagenics Group SE, is proud to offer the world's first quantitative GPBB (Glycogen Phosphorylase Isoenzyme BB) POCT solution, together with both qualitative and quantitative rapid testing solutions to meet diverse clinical needs.

🧠 Clinical Applications
✔ Stroke & Ischemic Stroke
✔ Acute Coronary Syndrome (ACS) / Heart Attack
✔ Pre-eclampsia

Why GPBB?

GPBB is an early biomarker of ischemic tissue injury, enabling clinicians to identify patients at risk during the critical early stage when timely intervention can make a significant difference.

Key Features

✅ Both Qualitative & Quantitative Rapid Testing
✅ CE Certified
✅ Lateral Flow Assay Technology
✅ Fast Turnaround Time
✅ Simple Workflow
✅ Reliable Performance

Designed for Emergency Departments, Cardiology, Neurology, Obstetrics, and Point-of-Care Testing (POCT), the GPBB Rapid Test supports faster clinical decision-making and improved patient care.

📩 Interested in distribution, OEM/private label, or clinical evaluation? We'd love to connect!

GenSure Biotech
Be Accurate. Be Reliable.